Rubius Therapeutics to Announce Second Quarter 2018 Financial Results
21 août 2018 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...
Rubius Therapeutics to Acquire Manufacturing Facility in Smithfield, Rhode Island to Produce Red Cell Therapeutics
25 juil. 2018 08h30 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...
Rubius Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
23 juil. 2018 08h30 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular...
Rubius Therapeutics Announces Pricing of Initial Public Offering
17 juil. 2018 22h44 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...